IQVIA (NYSE:IQV) Hits New 12-Month High – What’s Next?

IQVIA Holdings Inc. (NYSE:IQV)’s share price reached a new 52-week high during mid-day trading on Thursday . The company traded as high as $253.99 and last traded at $254.9950, with a volume of 83184 shares trading hands. The stock had previously closed at $249.28.

Analyst Ratings Changes

Several equities analysts have recently weighed in on the stock. TD Cowen increased their price objective on shares of IQVIA from $233.00 to $288.00 and gave the stock a “buy” rating in a research note on Wednesday, July 29th. BMO Capital Markets upped their target price on shares of IQVIA from $210.00 to $270.00 and gave the company an “outperform” rating in a report on Wednesday, July 29th. Stifel Nicolaus increased their price target on shares of IQVIA from $220.00 to $276.00 and gave the stock a “buy” rating in a research report on Wednesday, July 29th. Weiss Ratings upgraded shares of IQVIA from a “hold (c-)” rating to a “hold (c)” rating in a research note on Wednesday, July 15th. Finally, Barclays reissued an “overweight” rating on shares of IQVIA in a research report on Tuesday, July 28th. One equities research analyst has rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and three have issued a Hold rating to the company. According to MarketBeat, IQVIA currently has an average rating of “Moderate Buy” and an average target price of $241.88.

IQVIA Trading Up 1.6%

The stock has a 50-day moving average price of $213.32 and a two-hundred day moving average price of $187.52. The stock has a market capitalization of $42.82 billion, a PE ratio of 32.28, a PEG ratio of 2.17 and a beta of 1.18. The company has a debt-to-equity ratio of 2.18, a quick ratio of 0.71 and a current ratio of 0.71.

IQVIA (NYSE:IQV) last released its earnings results on Tuesday, July 28th. The medical research company reported $3.15 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.03 by $0.12. IQVIA had a net margin of 8.10% and a return on equity of 30.25%. The company had revenue of $4.37 billion during the quarter, compared to analyst estimates of $4.30 billion. During the same period in the prior year, the firm posted $2.81 EPS. The firm’s quarterly revenue was up 8.7% compared to the same quarter last year. IQVIA has set its FY 2026 guidance at 12.800-13.000 EPS. As a group, equities analysts forecast that IQVIA Holdings Inc. will post 11.57 earnings per share for the current year.

IQVIA announced that its Board of Directors has initiated a share buyback program on Thursday, May 7th that permits the company to repurchase $2.00 billion in shares. This repurchase authorization permits the medical research company to repurchase up to 6.8% of its shares through open market purchases. Shares repurchase programs are typically an indication that the company’s board of directors believes its stock is undervalued.

Insider Activity

In other IQVIA news, insider Keriann Cherofsky sold 558 shares of the stock in a transaction on Wednesday, July 29th. The stock was sold at an average price of $245.21, for a total value of $136,827.18. Following the completion of the sale, the insider owned 2,989 shares in the company, valued at approximately $732,932.69. This represents a 15.73% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, insider W Richard Staub sold 5,500 shares of the firm’s stock in a transaction dated Monday, August 3rd. The shares were sold at an average price of $232.68, for a total value of $1,279,740.00. Following the sale, the insider directly owned 13,312 shares in the company, valued at approximately $3,097,436.16. This represents a 29.24% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold 12,913 shares of company stock valued at $3,098,793 over the last 90 days. Company insiders own 1.70% of the company’s stock.

Institutional Trading of IQVIA

Several institutional investors have recently made changes to their positions in the business. Calamos Advisors LLC boosted its holdings in shares of IQVIA by 268.1% during the 4th quarter. Calamos Advisors LLC now owns 188,707 shares of the medical research company’s stock valued at $42,536,000 after purchasing an additional 137,441 shares during the last quarter. Concurrent Investment Advisors LLC increased its holdings in shares of IQVIA by 36.0% in the fourth quarter. Concurrent Investment Advisors LLC now owns 11,948 shares of the medical research company’s stock worth $2,693,000 after purchasing an additional 3,161 shares during the last quarter. Munich Reinsurance Co Stock Corp in Munich bought a new stake in shares of IQVIA in the fourth quarter worth about $3,444,000. Nippon Life Global Investors Americas Inc. lifted its position in shares of IQVIA by 36.6% in the fourth quarter. Nippon Life Global Investors Americas Inc. now owns 79,400 shares of the medical research company’s stock worth $17,898,000 after buying an additional 21,270 shares in the last quarter. Finally, BlackRock Inc. bought a new position in IQVIA during the second quarter valued at approximately $2,811,292,000. Hedge funds and other institutional investors own 89.62% of the company’s stock.

IQVIA Company Profile

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.